Cargando…

Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment Failure in a Population-Based Cohort

Introduction: Second-generation long-acting injectable antipsychotics (SG-LAIAs) may improve outcomes compared to other antipsychotics. Real-world studies using linked administrative databases play an important role in assessing the comparative effectiveness of antipsychotic medications. Methods: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janzen, Donica, Bolton, James M., Leong, Christine, Kuo, I fan, Alessi-Severini, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160742/ https://www.ncbi.nlm.nih.gov/pubmed/35662722 http://dx.doi.org/10.3389/fphar.2022.879224

Ejemplares similares

Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study
por: Janzen, Donica, et al.
Publicado: (2022)

Risk of long-term benzodiazepine and Z-drug use following the first prescription among community-dwelling adults with anxiety/mood and sleep disorders: a retrospective cohort study
por: Brandt, Jaden, et al.
Publicado: (2021)

Second Generation Long-Acting Injectable Antipsychotics in Africa: About a Case
por: Galvañ, J., et al.
Publicado: (2023)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics
por: Pompili, Maurizio
Publicado: (2020)

Comparison of hospitalizations in patients on first generation versus second generation long acting injectable (LAI) antipsychotics
por: Rasool, Seemab, et al.
Publicado: (2021)

Evaluation of oral antipsychotic supplementation of select second-generation long-acting injectable antipsychotics in an acute-care psychiatric setting
por: Alastanos, Jennifer N., et al.
Publicado: (2019)

Second‐generation antipsychotic long‐acting injections in bipolar disorder: Systematic review and meta‐analysis
por: Prajapati, Asta R., et al.
Publicado: (2018)

Corrigendum: Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics
por: Pompili, Maurizio
Publicado: (2020)

Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary
por: Takács, P., et al.
Publicado: (2019)

An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use
por: VandenBerg, Amy M.
Publicado: (2022)

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
por: Přikryl, Radovan, et al.
Publicado: (2012)

Comment on “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use”
por: Still, Daniel, et al.
Publicado: (2023)

Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction
por: Brasso, Claudio, et al.
Publicado: (2023)

Teetering on the Edge: Second-Degree Atrioventricular Block Following Long-Acting Second-Generation Antipsychotic
por: Harrisingh, Kamahl, et al.
Publicado: (2023)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations
por: Liu, Yifei, et al.
Publicado: (2023)

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
por: Pilon, Dominic, et al.
Publicado: (2017)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Population pharmacokinetics and dosing of long-acting injectable antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Long-acting injectable antipsychotics during pregnancy: An update
por: Paraschakis, A., et al.
Publicado: (2021)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis
por: Park, Seon-Cheol, et al.
Publicado: (2018)

Comparative Efficacy of First and Second Generation long-acting injectable antipsychotic upon schizophrenic patients: a systematic review and network metaanalysis.
por: Medrano, R., et al.
Publicado: (2023)

Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil
por: Fulone, Izabela, et al.
Publicado: (2021)

The regulatory effects of second-generation antipsychotics on lipid metabolism: Potential mechanisms mediated by the gut microbiota and therapeutic implications
por: Chen, Hui, et al.
Publicado: (2023)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics
por: Kheloussi, Steven, et al.
Publicado: (2022)

Response to comment on the recently published article “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use”
por: VandenBerg, Amy M.
Publicado: (2023)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
por: Toja-Camba, Francisco José, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

The use of long-acting injectable antipsychotics in an acute psychiatric unit
por: Ortega-Hernández, G., et al.
Publicado: (2023)

Prescription trends of antiseizure medications before and during the COVID-19 pandemic
por: Lavu, Alekhya, et al.
Publicado: (2023)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Psychotropic Medication Use Before and During COVID-19: A Population-Wide Study
por: Leong, Christine, et al.
Publicado: (2022)

Editorial: Antipsychotics of New Generation: Where Are We now?
por: Lipina, Tatiana V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qql7cgi05em4u7n31konftmce6